NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

ALEX TORDOFF is relishing the prospect of fulfilling a lifelong dream as he saddles up for his Defender Burghley Horse Trials debut.

HBAR tests key support at $0.23 after a 3% pullback Friday, with resistance forming near $0.24. Bullish catalysts emerge as ...

The Air Force has issued guidance on how transgender Airmen and Guardians will be involuntarily discharged, making it the ...